Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19006269 | 0.81 | PIK3CD (0.39) | PIK3CDPIK3CAPIK3CBL3MBTL1KDM4E | |
| SCHEMBL17397203 | 0.81 | MAPT (0.44) | PIK3CDBRD4L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL17397089 | 0.81 | PIK3CD (0.38) | PIK3CDPIK3CAPIK3CBSLC11A2 | |
| SCHEMBL19006268 | 0.81 | PIK3CD (0.38) | PIK3CDPIK3CAPIK3CBSLC11A2 | |
| SCHEMBL18837505 | 0.81 | PIK3CD (0.38) | PIK3CDPIK3CAPIK3CBSLC11A2 | |
| SCHEMBL18988878 | 0.79 | L3MBTL1 (0.37) | PIK3CDPIK3CABRD4L3MBTL1POLB | |
| SCHEMBL17397172 | 0.78 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBL3MBTL1KDM4E | |
| SCHEMBL18988886 | 0.78 | L3MBTL1 (0.34) | PIK3CDPIK3CABRD4L3MBTL1POLB | |
| SCHEMBL17397095 | 0.78 | L3MBTL1 (0.34) | PIK3CDPIK3CABRD4L3MBTL1ALDH1A1 | |
| SCHEMBL18988989 | 0.76 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| WO-2017103825-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017103825-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-06-22 | — | — | WO | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| EP-3164400-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | Lupin Limited (IN) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001855-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016001855-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R1, PIK3R4 | PIK3CD 5/4885PIK3CA 4/4885PIK3CB 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.